Galectin Therapeutics, Inc. (GALT)
4.04
-0.10
(-2.42%)
USD |
NASDAQ |
Sep 09, 15:06
Galectin Therapeutics Shareholders Equity (Quarterly) : -136.85M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -136.85M |
| March 31, 2026 | -130.24M |
| December 31, 2025 | -126.20M |
| September 30, 2025 | -123.58M |
| June 30, 2025 | -117.17M |
| March 31, 2025 | -112.26M |
| December 31, 2024 | -103.07M |
| September 30, 2024 | -92.48M |
| June 30, 2024 | -82.15M |
| March 31, 2024 | -71.09M |
| December 31, 2023 | -60.24M |
| September 30, 2023 | -50.87M |
| June 30, 2023 | -51.13M |
| March 31, 2023 | -42.65M |
| December 31, 2022 | -32.19M |
| September 30, 2022 | -22.34M |
| June 30, 2022 | -15.22M |
| March 31, 2022 | -6.193M |
| December 31, 2021 | 2.616M |
| September 30, 2021 | 9.249M |
| June 30, 2021 | 17.12M |
| March 31, 2021 | 18.23M |
| December 31, 2020 | 24.19M |
| September 30, 2020 | 31.54M |
| June 30, 2020 | 37.01M |
| Date | Value |
|---|---|
| March 31, 2020 | 42.75M |
| December 31, 2019 | 45.60M |
| September 30, 2019 | 49.48M |
| June 30, 2019 | 51.62M |
| March 31, 2019 | 6.842M |
| December 31, 2018 | 6.898M |
| September 30, 2018 | 8.97M |
| June 30, 2018 | 9.775M |
| March 31, 2018 | 2.648M |
| December 31, 2017 | 1.193M |
| September 30, 2017 | 2.67M |
| June 30, 2017 | 5.817M |
| March 31, 2017 | 9.635M |
| December 31, 2016 | 12.02M |
| September 30, 2016 | 12.03M |
| June 30, 2016 | 14.61M |
| March 31, 2016 | 19.54M |
| December 31, 2015 | 25.05M |
| September 30, 2015 | 19.79M |
| June 30, 2015 | 24.77M |
| March 31, 2015 | 28.68M |
| December 31, 2014 | 27.97M |
| September 30, 2014 | 29.94M |
| June 30, 2014 | 32.45M |
| March 31, 2014 | 34.96M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 14.83M |
| Total Liabilities (Quarterly) | 151.68M |
| Debt to Equity Ratio | -1.007 |
| Current Ratio | 0.0967 |
| Net Debt Paydown Yield | -1.94% |